Strategic growth aligned with clear vision:
Strong growth continues at 30 percent

• Net sales amounted to 18,3 MSEK (14,0), an increase of 30 percent over the same period in 2021.
• Operating result amounted to 0.1 MSEK (-9,4).
• Net result after financial items amounted to -0,2 MSEK (-9,7).
• Earnings per share were 0,00 SEK (-0,15).
• Cash Balance amounted to 7,3 MSEK (36,3).
• Average Daily Treatment Revenue (ADTR)* was 201 TSEK (163), an increase of 23 percent over the same period in 2021.

• The Annual Report for 2021 was published 28 April 2022.

• The Annual General Meeting was held on 19 May 2022.

• Catarina Mård Löwenadler became Chief Executive Officer of Dignitana on 19 May 2022.

• The company appointed Ulf Jönsson as Chief Financial Officer beginning 1 July 2022.

• Dignitana AB secured a line of credit in the amount of SEK 10 million from the company's largest shareholder, Agartha AB, to support the strategic growth of the company.

• The American Medical Association reaffirmed their policy supporting scalp cooling and reimbursement for the treatment.

Key Figures

DIGNITANA GROUP Q2 Q2 Q1-Q2 2022 Q1-Q2 2021 Full Year 2021
2022 2021
Net sales, TSEK 18 14 34 148 27 203  57 073
284 038
Total revenues, TSEK 24 17 40 777 31 331  62 376
067 174
Net profit after -232 -9 -6 740 -17 324 -43 076
financial items, TSEK 660
Cash and bank balances, 7 312 36 7 312 36 333  14 501
TSEK 333
Earnings per share 0,00 -0,15 -0,10 -0,28 -0,66
before and after
dilution, SEK
Average Daily Treatment 201 163 190 146 147
Revenue*, TSEK

* ADTR includes pay-per-treatment revenue from patients and facilities. Does not include lease revenue or disposable sales.

All financial reports are available at www.dignitana.com/investor-relations/financial-reports/

This disclosure contains information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 18-08-2022 08:00 CET.